



Omega-3 Polyunsaturated Fatty Acids Decrease Aortic Valve Disease Through the Resolvin E1 and ChemR23 Axis

BACKGROUND: Aortic valve stenosis (AVS), which is the most common valvular heart disease, causes a progressive narrowing of the aortic valve as a consequence of thickening and calcification of the aortic valve leaflets. The beneficial effects of omega-3 polyunsaturated fatty acids (n-3 PUFAs) in cardiovascular prevention have recently been demonstrated in a large randomized, controlled trial. In addition, n-3 PUFAs serve as the substrate for the synthesis of specialized proresolving mediators, which are known by their potent beneficial anti-inflammatory, proresolving, and tissue-modifying properties in cardiovascular disease. However, the effects of n-3 PUFA and specialized proresolving mediators on AVS have not yet been determined. The aim of this study was to identify the role of n-3 PUFA-derived specialized proresolving mediators in relation to the development of AVS.

METHODS: Lipidomic and transcriptomic analyses were performed in human tricuspid aortic valves. *Apoe*^{-/-} mice and wire injury in C57BL/6J mice were used as models for mechanistic studies.

RESULTS: We found that n-3 PUFA incorporation into human stenotic aortic valves was higher in noncalcified regions compared with calcified regions. Liquid chromatography tandem mass spectrometry-based lipid mediator lipidomics identified that the n-3 PUFA-derived specialized proresolving mediator resolvin E1 was dysregulated in calcified regions and acted as a calcification inhibitor. *Apoe*^{-/-} mice expressing the *Caenorhabditis elegans* Fat-1 transgene (*Fat-1*^{tg}×*Apoe*^{-/-}), which enables the endogenous synthesis of n-3 PUFA and increased valvular n-3 PUFA content, exhibited reduced valve calcification, lower aortic valve leaflet area, increased M2 macrophage polarization, and improved echocardiographic parameters. Finally, abrogation of the resolvin E1 receptor ChemR23 enhanced disease progression, and the beneficial effects of *Fat-1*^{tg} were abolished in the absence of ChemR23.

CONCLUSIONS: n-3 PUFA-derived resolvin E1 and its receptor ChemR23 emerge as a key axis in the inhibition of AVS progression and may represent a novel potential therapeutic opportunity to be evaluated in patients with AVS.

Gonzalo Artiach, MSci
Miguel Carracedo, PhD
Oscar Plunde, MD
Craig E. Wheelock, PhD
Silke Thul, PhD
Peter Sjövall , PhD
Anders Franco-Cereceda,
MD, PhD
Andres
Laguna-Fernandez, PhD
Hildur Arnardottir, PhD
Magnus Bäck, MD, PhD

Key Words: calcification, physiologic
■ fatty acids, omega-3 ■ heart valve
diseases ■ inflammation ■ lipids

Sources of Funding, see page 787

© 2020 The Authors. *Circulation* is published on behalf of the American Heart Association, Inc., by Wolters Kluwer Health, Inc. This is an open access article under the terms of the [Creative Commons Attribution](https://creativecommons.org/licenses/by/4.0/) License, which permits use, distribution, and reproduction in any medium, provided that the original work is properly cited.

<https://www.ahajournals.org/journal/circ>

Clinical Perspective

What Is New?

- Omega-3 polyunsaturated fatty acids (n-3 PUFAs) have not previously been associated with valvular heart disease.
- This study shows that human stenotic aortic valves contained decreased levels of n-3 PUFAs and that n-3 PUFA treatment decreased aortic valve calcification and aortic valve leaflet area in murine models, concomitant with improved aortic valve hemodynamics.
- The proresolving lipid mediator resolvin E1, which is derived from the n-3 PUFA eicosapentaenoic acid, exerted protective effects on valvular interstitial cell calcification and valvular inflammation through its receptor ChemR23.

What Are the Clinical Implications?

- The n-3 PUFA/resolvin E1/ChemR23 axis emerges as a protective pathway in aortic stenosis.
- Clinical evaluation of n-3 PUFA treatment may open up novel therapeutic opportunities for preventing the progression of aortic valve stenosis.

Aortic valve stenosis (AVS) is the most common valvular heart disease and major cause of heart failure and increased cardiovascular mortality. When severe, AVS causes significant cardiac outflow obstruction with 1-year mortality rate reaching 60% for severe symptomatic AVS.¹ The progressive aortic valve narrowing develops as a consequence of an increased thickening and calcification of the aortic valve leaflets.² A vast majority of clinical trials has failed to stop the progression of AVS,³ and for that reason, the only available therapeutic treatment relies on aortic valve prosthesis implantation.⁴

A recent clinical trial demonstrated that eicosapentaenoic acid (EPA) ethyl ester in high doses conferred a 25% relative risk reduction in major cardiovascular events compared with placebo, including cardiovascular death, nonfatal myocardial infarction, nonfatal stroke, coronary revascularization, and hospitalization for unstable angina as outcome.⁵ Omega-3 polyunsaturated fatty acids (PUFAs), especially EPA and docosahexaenoic acid (DHA), are known for their anti-inflammatory and proresolving properties by serving as substrates for the biosynthesis of a unique class of bioactive lipid mediators called specialized proresolving lipid mediators (SPMs).⁶

The SPM-derived from EPA and DHA include the E-series and D-series resolvins, protectins, and maresins. Under certain conditions, EPA- and DHA-derived SPMs are actively formed by a wide variety of cells and are responsible for the resolution of the

inflammatory process.⁷ Resolvins mediate their signaling through the specific G-protein-coupled receptors, denoted ChemR23, GPR18, ALX/FPR2, and GPR32.⁸ Indeed, beneficial effects of resolvin E1 (RvE1) through ChemR23 signaling have been demonstrated in the context of atherosclerosis,⁹ intimal hyperplasia,¹⁰ and vascular calcification.¹¹ However, the role of n-3 PUFAs, specifically the effect of RvE1 through ChemR23 in the context of AVS and valve calcification and inflammation, remains unknown.

The aim of this study was to identify the role of n-3 PUFA-derived SPMs in relation to the development of AVS. In human stenotic valves, we identified the n-3 PUFA-derived SPMs RvE1 and its receptor ChemR23, and we studied the valvular effects in 2 different mouse models, demonstrating the beneficial effects mediated through the RvE1/ChemR23 axis.

METHODS

Patients

Tricuspid human aortic valves were obtained from 96 patients undergoing aortic valve replacement surgery. The study was approved by the local ethics committee (2012/1633) and was in agreement with the Declaration of Helsinki. All patients gave informed consent.

Liquid Chromatography–Tandem Mass Spectrometry

Valve samples were placed in ice-cold methanol containing deuterated internal standards representing each chromatographic region of identified lipid mediators (500 pg each) before processing to facilitate quantification and assessment of sample recovery. Samples were homogenized and proteins were precipitated, followed by solid-phase extraction with Isolute C18 columns (Biotage, Uppsala, Sweden)¹² and targeted liquid chromatography–tandem mass spectrometry as previously described.^{13,14} The system consisted of Waters XevoTQS triple quadrupole equipped with Acquity UPLC System from Waters Corporation and an autosampler cooled to 5°C (Milford, MA). An Acquity UPLC BEH (Ethylene Bridged Hybrid) C18 column (130 Å, 1.7 μm, 2.1×150 mm) equipped with a precolumn (Acquity UPLC C18 VanGuard Pre-Column, 130 Å, 1.7 μm, 2.1×5 mm; Milford, MA) was used with gradients A (0.1% acetic acid in water) and B (acetonitrile/isopropanol; 90:10 [vol/vol–1]) from 80:20 (vol/vol–1) to 0:100 (vol/vol–1) in 17 minutes at a flow rate of 0.5 mL·min⁻¹, which was then equilibrated to initial conditions for 2.5 minutes. To monitor and quantify levels of lipid mediators, a multiple reaction monitoring method was developed with a signature ion pairs Q1 (parent ion) to Q3 (characteristic daughter ion) for each molecule (eg, Q1>Q3 for RvE1 349>195; resolvin D3 (RvD3), 375>147; and leukotriene B4, 339>195). Linear calibration curves were obtained using synthetic standards for each lipid mediator, which gave R² values of 0.98 to 0.99. Data acquisition was performed in the negative ionization mode, and identification was conducted in accordance with published criteria.¹⁴

Animals

Animals were bred and kept under standard housing conditions, and all animal experiments were conducted in accordance with guidelines from Directive 2010/63/EU of the European Parliament on the protection of animals used for scientific purposes and were approved by the Ethical Committee of Northern Stockholm (Ethical Permit N28/15).

ChemR23^{-/-} mice were purchased from Deltagen. Male mice were used in all experiments. Double-knockout Apoe^{-/-}×ChemR23^{-/-} were generated by crossbreeding ChemR23^{-/-} mice on a C57BL/6J background with apolipoprotein E-deficient (Apoe^{-/-}) mice also on C57BL/6J background. C57BL/6J mice hemizygous for the transgene *Caenorhabditis elegans* Fat-1^{tg} were a gift from Professor Joan Clària (Barcelona, Spain). The Fat-1^{tg} encodes a desaturase that converts n-6 to n-3 PUFA.¹⁵ Fat-1^{tg}×Apoe^{-/-}×ChemR23^{+/+} and Fat-1^{tg}×Apoe^{-/-}×ChemR23^{-/-} mice were generated by crossbreeding Fat-1 transgenic mice with the Apoe^{-/-} strains described above.

Statistics

Results are expressed as mean±SEM. Statistical significance of differences for normally distributed data were assessed with paired or unpaired Student *t* test when comparing 2 groups and with 1-way or 2-way ANOVA as appropriate followed by a Holm-Sidak test for multiple comparisons. Repeated measures analysis was performed when appropriate and possible. Mixed-effects ANOVA was applied when accounting for technical replicates. Partial *R*² was established for the associations within and between morphological and echocardiographic parameters. In brief, partial *R*² was calculated for the quantitative predictor as the percent reduction in the error sum of squares between 2 models: the first model including genotype as a predictor and the second model including the quantitative predictor.¹⁶ For categorical data, statistical significance was assessed with the Fisher exact test. Statistical significance was assigned at *P*<0.05. Statistical analyses were performed with GraphPad Prism 8 (GraphPad Software Inc, La Jolla, CA) and NCSS version 9 (LLC, East Kaysville, UT).

Details about experimental animals (Tables IV through VII and IX and Figures I and II in the Data Supplement), human data (Tables I, II, and VIII in the Data Supplement), materials (Table III in the Data Supplement), and supplemental methods are provided online in the Data Supplement. One author had full access to all the data in the study and takes responsibility for its integrity and the data analysis. Data, methods, and materials will be available to other researchers for the purposes of reproducing the results or replicating the procedures (available at the authors' laboratories).

RESULTS

n-3 PUFA Content in Human Aortic Valves

The fatty acid content in human aortic valves, as determined by gas chromatography analysis of noncalcified aortic valve tissue derived from n=21 patients, is shown in the Table. Comparing noncalcified and calcified tissue derived from the same aortic valve (Figure 1A) revealed

Table. Gas Chromatography Analyses of Noncalcified Aortic Valve Tissue

Fatty Acid	Percent of Total
Palmitic acid, C16_0	24.28±0.39
Stearic acid, C18_0	12.80±0.71
Oleic acid, C18_1n9	24.50±1.29
Linoleic acid, C18_2n6	16.67±0.67
α-Linolenic acid, C18_3n3	0.47±0.04
Γ-Linolenic acid, C18_3n6	0.18±0.01
Eicosatrienoic acid, C20_3n6	1.04±0.09
Arachidonic acid, C20_4n6	8.66±0.66
EPA, C20_5n3	0.87±0.09
Docosatetraenoic acid, C22_4n6	0.82±0.07
Docosapentaenoic acid, C22_5n6	0.26±0.04
Docosapentaenoic acid, C22_5n3	0.88±0.15
DHA, C22_6n3	2.27±0.13
HS-omega-3 index	3.13±0.20

Data are presented as mean±SEM; n=21. DHA indicates docosahexaenoic acid; and EPA, eicosapentaenoic acid.

that the HS-omega-3 index, an overall measure of the n-3 PUFA content, was significantly higher in noncalcified parts compared with calcified parts of the aortic valve (Figure 1B). There were no significant differences between the characteristics of patients with aortic valve HS-omega-3 index above and below median (Table I in the Data Supplement). However, patients who had a history of slow AVS progression exhibited a higher HS-omega-3 in noncalcified aortic valve regions compared with patients with rapidly progressing AVS (Figure 1C), although the limited number of observations did not attain statistical significance (*P*=0.055). In addition, principal component analysis revealed differential transcriptomic profiles between patients with high and low HS-omega-3 index in the noncalcified and also calcified human aortic valve tissue (Figure 1D). The underlying GSEA KEGG pathways differentiating high and low HS-omega-3 index in noncalcified and calcified human aortic valve tissue, respectively, are shown in Table II in the Data Supplement.

Resolvins and Leukotrienes Are Dysregulated in Calcified Aortic Valve Tissue

Because the observed changes in aortic valve fatty acid content may alter the substrate availability for downstream lipid mediator formation, a targeted lipid mediator lipidomics by liquid chromatography–tandem mass spectrometry was performed. Here, we identified 2 n-3 PUFA-derived SPMs in human valves, DHA-derived RvD3 (4S,11R,17S-trihydroxy-5Z,7E,9E,13Z,15E,19Z-DHA) and EPA-derived RvE1




Figure 1. HS-omega-3 index is decreased in calcified aortic valve tissue and is lower in noncalcified valve tissue of aortic valve stenosis (AVS) fast progressors.

A, Aortic valves from patients undergoing aortic valve replacement were dissected into noncalcified and calcified valve tissue. **B**, HS-omega-3 index measured by gas chromatography in calcified and noncalcified valve tissue from the same patients ($n=14$). **C**, HS-omega-3 index in patients with AVS with slow and fast progression in noncalcified ($n=5$ and $n=6$, respectively) valve tissue. Data are presented as individual values; horizontal lines represent mean \pm SEM. Statistical significance was evaluated using either paired (**B**) or unpaired (**C**) Student *t* test. * $P<0.05$. **D**, Transcriptomics-based principal component (PC) analysis of noncalcified ($n=6$ high, $n=6$ low HS-omega-3 index) and calcified ($n=12$ high, $n=9$ low HS-omega-3 index) human valve tissue. The 3 axes represent the principal components displaying maximum variability between data sets, in which PC1 represents the axis with most variability.

(5S,12R,18R-trihydroxy-6Z,8E,10E,14Z,16E-EPA), in both noncalcified and calcified valve tissue. Identification of lipid mediators was performed in accordance with published criteria¹⁴ that included matching retention time and at least 6 diagnostic ions for each. The tandem mass spectrometry spectra for RvE1 and RvD3 matched those originally identified^{17,18} and are reported as follows for RvD3: 375=M-H; 357=M-H-H₂O; 339=M-H-2H₂O; 313=M-H-H₂O-CO₂; 295=M-H-2H₂O-CO₂; 259=277-H₂O; 177=195-H₂O; 159=195-2H₂O; 147=165-H₂O) and RvE1 (349=M-H; 331=M-H-H₂O; 313=M-H-2H₂O; 305=M-H-CO₂; 273=291-H₂O; 269=M-H-2H₂O-CO₂; 255=291-2H₂O; 229=291-H₂O-CO₂; 205=223-H₂O; 179=223-CO₂; and 177=223-H₂O. Quantification with multiple reaction monitoring demonstrated that RvE1 levels were significantly lower in calcified compared with noncalcified tissue (Figure 2A and 2B). A similar pattern was observed for RvD3, although the difference between calcified and noncalcified tissue did not reach statistical significance (Figure 2C). In contrast, the pro-inflammatory n-6 PUFA-derived lipid mediator leukotriene B4 was significantly higher in calcified compared with noncalcified tissue (Figure 2D).

The RvE1 Receptor ChemR23 Is Expressed in Human Aortic Valves and RvE1 Reduces Calcification in Human Valvular Interstitial Cells In Vitro

To determine whether n-3 PUFA-derived SPMs can exert local effects within the aortic valve, mRNA levels for the SPM receptors ChemR23, GPR18, GPR32, and ALX/FPR2 were explored in noncalcified tissue from 64 human aortic valves. Gene expression analysis revealed ChemR23, encoding the RvE1 receptor, as the predominant SPM receptor in human aortic valves (Figure 3A, top), whereas the differential expression of the same receptors between calcified and noncalcified regions was similar (Figure 3A, bottom). Moreover, ChemR23 protein expression detected by immunohistochemistry was widely distributed in the fibrosa, spongiosa, and ventricularis layers of human aortic valves and in calcified and noncalcified regions (Figure 3B), colocalizing with the valvular interstitial cell (VIC) markers smooth muscle actin and vimentin by immunofluorescence (Figure 3C and 3D).

Given the expression of ChemR23 in VICs and the decreased levels of RvE1 in calcified valve tissue, we

next studied the effect of RvE1 on VIC calcification induced by a high-phosphate media. RvE1 significantly decreased calcification of human VICs compared with vehicle (Figure 3E and 3F).

n-3 PUFA Concentrations Are Higher and n-6 PUFA Concentrations Are Lower in Aortic Valve Leaflets of Fat-1^{tg}×Apoe^{-/-} Mice Compared With Apoe^{-/-} Mice

To test the applicability of the beneficial effects of n-3 PUFA on aortic valve disease (AVD) under different conditions, we established the expression of the *C elegans* Fat-1^{tg} in Apoe^{-/-} mice, which enables the endogenous production of n-3 PUFAs. n-3 PUFAs and n-6 PUFAs were measured in aortic valve leaflet regions of Fat-1^{tg}×Apoe^{-/-} and Apoe^{-/-} mice using time-of-flight secondary ion mass spectrometry. Spatially resolved mass spectrometric data were obtained by time-of-flight secondary ion mass spectrometry analysis of tissue sections containing the aortic valve region. The data were used to generate ion images, which display the lateral distribution of specific molecular species within the analysis area and mass spectra from selected structures on the tissue section surface, including different valve leaflet regions. The aortic root, identified by optical microscopy (Figure 4A), exhibited presence of phosphatidylethanolamine on the tissue surface, cholesterol in atherosclerotic plaque regions, and heme in the tissue-free area, indicating blood remnants (Figure 4B and 4C, left). Spatially resolved fatty acid data were then extracted by generating mass spectra from regions of interest exclusively corresponding to valve leaflet regions (Figure 4B and 4C, center and right).

Analysis of the fatty acid signal intensities in all mass spectra of the central regions of the valve leaflets demonstrated significantly higher relative concentrations of n-3 PUFAs (EPA, docosapentaenoic acid) and significantly lower relative concentrations of n-6 PUFAs (arachidonic acid) in Fat-1^{tg}×Apoe^{-/-} mice compared with Apoe^{-/-} mice (Figure 4D and 4E, respectively). In addition, and consistent with the previous observation, Fat-1^{tg}×Apoe^{-/-} mice exhibited a significant increase in HS-omega-3 index in ventricular myocardium (Figure 4F). Full gas chromatography analysis in ventricular myocardium of Apoe^{-/-} and Fat-1^{tg}×Apoe^{-/-} is shown in Table IV in the Data Supplement.

Fat-1^{tg} Halts Whereas Targeted Deletion of ChemR23 Increases Echocardiographic Progression in Apoe^{-/-} Mice

Transaortic peak velocity (Vmax) and aortic valve cusp separation were evaluated at 52, 64, and 72 weeks of age. Apoe^{-/-} mice had progressively increased Vmax with age (Figure 5A) to velocities above normal mice (>1.5 m/s) at

72 weeks.¹⁹ Fat-1^{tg}×Apoe^{-/-} mice exhibited a significantly reduced Vmax (Figure 5A), a significantly increased aortic valve cusp separation (Figure 5B), and reduced left ventricular mass (Table V in the Data Supplement) at 72 weeks compared with nontransgenic Apoe^{-/-} mice (Figure 5B). The full echocardiographic analysis determined at the study end point at 72 weeks is shown in Table V in the Data Supplement. There were no significant differences in heart rate between the different groups at any age (Tables V and VI in the Data Supplement).

On the basis of the results obtained in the analysis of human aortic valves (see above and Figures 1 through 3), the RvE1/ChemR23 axis was abrogated by genetic deletion of ChemR23 in the Apoe^{-/-} model to determine the mechanisms through which n-3 PUFAs induced the beneficial effects on the aortic valve. Apoe^{-/-}×ChemR23^{-/-} mice exhibited significantly increased Vmax and reduced cusp separation compared with Apoe^{-/-}×ChemR23^{+/+} mice, pointing to the ChemR23 receptor as a transducer of aortic valve protection (Figure 5A and 5B).

To establish whether the beneficial effects of an increased n-3 PUFA pathway were transduced through ChemR23, Fat-1^{tg} was introduced also in the Apoe^{-/-}×ChemR23^{-/-} mice. The beneficial effects observed in Fat-1^{tg}×Apoe^{-/-} (reduced Vmax and increased aortic cusp separation) were completely abolished in Fat-1^{tg}×Apoe^{-/-}×ChemR23^{-/-} mice (Figure 5A and 5B), suggesting a direct effect of n-3 PUFA-derived RvE1 signaling through ChemR23 in the progression of the disease. Vmax inversely correlated with cusp separation (adjusted $R^2=0.61$, $P<0.0001$; partial $R^2=0.36$, $P<0.0001$), supporting that the increased Vmax was a result of reduced cusp separation. The ejection fractions were in line with previous reports,²⁰ and no significant differences were observed between the 4 groups (Figure 5C). No regurgitations were observed in any mouse. Finally, echocardiographic evaluation of control (Apoe^{+/+}) ChemR23^{+/+}, ChemR23^{-/-}, Fat-1^{tg}×ChemR23^{+/+}, and Fat-1^{tg}×ChemR23^{-/-} mice did not reveal either increased gradients or reduced cusp separation, and no any apparent differences were observed between groups and time (Figure IA through ID in the Data Supplement).

Fat-1^{tg} Reduces Aortic Valve Leaflet Area and Targeted Deletion of ChemR23 Increases Aortic Valve Leaflet Area in Apoe^{-/-} Mice

In addition to the echocardiographic measures of aortic velocities and aortic cusp separation, morphological analysis supported beneficial effects of the Fat-1^{tg} through ChemR23 on aortic valve leaflet area. Fat-1^{tg}×Apoe^{-/-} mice exhibited reduced aortic valve leaflet area compared with nontransgenic mice in the presence but not in the absence of ChemR23. In contrast, Apoe^{-/-}×ChemR23^{-/-} mice




Figure 3. The resolvin E1 (RvE1) receptor ChemR23 is expressed in human aortic valves, and RvE1 reduces calcification in human valvular interstitial cells (VICs) in vitro.

A, Relative abundance of RNA encoding the specialized proresolving lipid mediator receptors ChemR23, GPR18, GPR32, and ALX/FPR2 in noncalcified human valve tissue ($n=64$; **top**), and difference in gene expression between calcified and noncalcified regions (**bottom**). **B**, Representative photomicrographs of ChemR23 immunohistochemical detection in human aortic valves. White space and dense purple deposits are found at sites of calcified nodules. Higher magnification images of 3 regions of interest (ROIs) display the presence of ChemR23 in the fibrosa (ROI 1), spongiosa (ROI 2), and ventricularis (ROI 3) layers. **C** and **D**, Representative immunofluorescence stainings of human aortic valves showing colocalization of VIC markers (smooth muscle actin [SMA]– and Vimentin-positive cells) and ChemR23. **E**, In vitro effects of RvE1 and quantification by Osteoimage Mineralization Assay of phosphate-induced calcification in VICs after 9 days. Data are presented as individual values, and horizontal lines represent mean \pm SEM. Statistical significance was evaluated with a mixed-effects ANOVA followed by Holm-Sidak multiple-comparison test; $n=3$ in duplicates. **F**, Representative photomicrographs of phosphate-treated VICs stained by Alizarin Red. * $P<0.05$.

by Alizarin Red staining. These analyses revealed that Fat-1^{tg} \times Apoe^{-/-} \times ChemR23^{+/+} mice exhibited a significantly reduced calcification compared with Apoe^{-/-} \times ChemR23^{+/+} mice. In addition, Apoe^{-/-} \times ChemR23^{-/-} mice exhibited significantly higher leaflet calcification compared with Apoe^{-/-} \times ChemR23^{+/+} in both the absence and presence of Fat-1^{tg} (Figure 7A). Moreover, leaflet calcification correlation with aortic valve leaflet area (adjusted $R^2=0.38$, $P=0.0009$; partial $R^2=0.02$, $P=0.35$), Vmax (adjusted $R^2=0.49$, $P<0.0001$; partial $R^2=0.001$, $P=0.83$), and cusp separation (adjusted $R^2=0.37$, $P=0.0011$; partial $R^2=0.001$, $P=0.82$) was significant in adjusted models, whereas the nonsignificant partial R^2 supported genotype as the predictor for the observed associations. No significant differences in blood cell counts were observed between the different groups (Table V in the Data Supplement).

Fat-1^{tg} Induces M2 Macrophage Polarization

Further characterization was performed to establish how the observed hemodynamic and morphological effects were related to changes in the inflammatory response. Because macrophages represent a major immune cell population in the stenotic valves and because macrophage polarization is a crucial step in the resolution of inflammation, immunohistochemistry for different macrophage markers in the mouse aortic valves was performed. Whereas the proportion of leaflet area containing CD68 did not significantly differ between the groups (Figure 7B), a significantly increased proportion of the M2 macrophage markers CD206 and arginase 1 was observed in Fat-1^{tg} \times Apoe^{-/-} mice (Figure 7C and 7D), which was lost in mice lacking ChemR23 (Figure 7D). In contrast, the M1 macrophage marker inducible nitric oxide synthase was not significantly different between the 4 groups (Figure 7E).




Figure 4. Omega-3 polyunsaturated fatty acids (PUFAs) are higher and n-6 PUFAs are lower in valve leaflets of Fat-1^{tg}xApoe^{-/-} compared with Apoe^{-/-} mice.

A, Optical micrograph of an aortic root section of a Fat-1^{tg}xApoe^{-/-} mouse. Red squares indicate areas (500×500 μm²) for focused analyses of valve leaflets and valve insertion, respectively. **B** and **C**, Time-of-flight secondary ion mass spectrometry (TOF-SIMS) data from 2 different regions of the valve leaflet area with ion images of (left) overlay image of phosphatidylethanolamine (PE) in red, cholesterol in green, and heme in blue (left); total ion image with region of interest (ROI) used for extraction of mass spectrum of valve leaflet indicated in gray (middle); and image of the added signal intensity of eicosapentaenoic acid (EPA; C20:5n3), docosahexaenoic acid (DHA; C22:6n3), and docosapentaenoic acid (DPA; C22:5n3; right). Brighter pixels in the ion images correspond to higher signal intensities. **D**, n-3 PUFAs (DHA, EPA, and DPA) and **(E)** n-6 PUFAs (arachidonic acid [C20:4n6] and adrenic acid [C22:4n6]) normalized TOF-SIMS signal intensities (n=3 animals per group; each observation is the average of 3 independent leaflet regions at different valve levels) in mass spectra acquired from valve leaflets. **F**, HS-omega-3 index in ventricular myocardium measured by gas chromatography in Apoe^{-/-} compared with Fat-1^{tg}xApoe^{-/-} mice (n=6 per group). Data are presented as individual values with horizontal lines representing mean±SEM. Statistical significances were evaluated with either a Student *t* test or a 2-way repeated measures ANOVA followed by Holm-Sidak multiple-comparison test. **P*<0.05. *****P*<0.0001.

ChemR23 Correlates With M2 Macrophage Markers in Human Aortic Valves

In line with the findings in murine valves, we found a strong correlation between ChemR23 and CD206 mRNA levels in both calcified and noncalcified parts of human aortic valves (Table VIII in the Data Supplement). In addition, ChemR23 was positively and significantly correlated with the M2 macrophage markers CD163, CD209, CD200R1, and heme oxygenase 1 (Table VIII in the Data Supplement).

Targeted Deletion of ChemR23 Induces Higher V_{max} and Increased Thickening of the Aortic Valve After Aortic Valve Wire Injury

Because n-3 PUFAs reduced aortic valve obstruction, thickness, and calcification by means of ChemR23 in

the context of hypercholesterolemia, we finally evaluated the effect of ChemR23 deletion of aortic valve hemodynamics and morphology in the absence of hypercholesterolemia. A second model of AVD was therefore established for this study by using normolipidemic ChemR23^{+/+} (C57BL/6J) and ChemR23^{-/-} mice and applying the protocol of aortic valve wire injury introduced by Honda et al²¹ and called mild injury by Niepmann et al.²² Consistent with the aforementioned results in Apoe^{-/-} mice, the V_{max} was significantly higher in ChemR23^{-/-} mice 16 weeks after aortic valve injury compared with ChemR23^{+/+} mice, with no significant difference in ejection fraction between the 2 groups. Tissue morphology analysis revealed that ChemR23^{-/-} mice exhibited significantly increased aortic valve leaflet thickness compared with ChemR23^{+/+} mice (Figure IIA through IIC in the Data Supplement). No significant




Figure 5. Fat-1^{tg} halts whereas targeted deletion of ChemR23 increases echocardiographic progression in Apoe^{-/-} mice.

A, Transaortic peak velocity, **(B)** cusp separation, and **(C)** ejection fraction in 52-, 64-, and 72-week-old Apoe^{-/-}xChemR23^{+/+} (n=12), Apoe^{-/-}xChemR23^{-/-} (n=13), Fat-1^{tg}xApoe^{-/-}xChemR23^{+/+} (n=6), and Fat-1^{tg}xApoe^{-/-}xChemR23^{-/-} (n=13) mice. Representative color Doppler, Doppler, and M-mode tracings are shown in 72-week-old mice. Data are presented either as individual values with horizontal lines representing mean±SEM or as mean±SEM. Statistical significances were evaluated with either a 1- or 2- way repeated measures ANOVA followed by Holm-Sidak multiple-comparison test. Results are pooled from 2 independent experiments. *P<0.05; **P<0.01; ***P<0.001; ****P<0.0001.

differences in blood cell counts were observed between the 2 genotypes (Table IX in the Data Supplement).

DISCUSSION

This is the first study to indicate beneficial effects of n-3 PUFAs inhibiting aortic valve thickening and calcification and retarding AVD progression. This conclusion was based on several observations as discussed below. First, starting from observational analysis of human aortic valves, we demonstrated that decreased aortic valve

n-3 PUFA levels were associated with valve calcification, a specific transcriptomic profile, M2 macrophage markers, and a trend toward faster progression into severe AVS. Second, we detected high levels of the n-3 PUFA-derived SPM RvE1 and its receptor ChemR23 in noncalcified valve tissue and showed anticalcifying effects of RvE1 on VICs. Third, by means of a combined strategy using different genetic targeting and several murine AVD models, we identified for the first time the presence of n-3 PUFAs in the mouse aortic valve and that the mechanisms behind the beneficial hemodynamic




Figure 6. Fat-1^{tg} reduces aortic valve leaflet area and targeted deletion of ChemR23 increases aortic valve leaflet area in Apoe^{-/-} mice. **A**, Aortic valve leaflet area in 72-week-old Apoe^{-/-}xChemR23^{+/+} (n=12), Apoe^{-/-}xChemR23^{-/-} (n=13), Fat-1^{tg}xApoe^{-/-}xChemR23^{+/+} (n=10), and Fat-1^{tg}xApoe^{-/-}xChemR23^{-/-} (n=13) mice and representative photomicrographs. Data are presented as mean±SEM. Statistical significance was determined with a 2-way ANOVA followed by Holm-Sidak multiple-comparison test. ****P<0.0001. **B**, Adjusted R² and partial R² for the correlation between aortic valve leaflet area and aortic valve leaflet thickness. **C**, Adjusted R² and partial R² for the correlation between transaortic peak velocity and aortic valve leaflet area. **D**, Adjusted R² and partial R² for the correlation between cusp separation and aortic valve leaflet area. Apoe^{-/-}xChemR23^{+/+} (n=12), Apoe^{-/-}xChemR23^{-/-} (n=13), Fat-1^{tg}xApoe^{-/-}xChemR23^{+/+} (n=6), and Fat-1^{tg}xApoe^{-/-}xChemR23^{-/-} (n=13) mice for all correlations.

effects were mediated by reduced leaflet area, calcification, and increased M2 macrophage polarization, transduced through the RvE1 receptor ChemR23. From these results, the n-3 PUFA/RvE1/ChemR23 axis emerges as a novel therapeutic opportunity for AVD.

Although the recently reported beneficial effects of high-dose EPA ethyl ester on cardiovascular events^{5,23} have renewed interest in n-3 PUFAs in cardiovascular prevention, their effects on AVS have remained unknown. By a combined lipidomic and transcriptomic approach, we demonstrate here the n-3 PUFA incorporation into human aortic valves, in the same range as previously reported in red blood cells²⁴ and myocardial biopsies,²⁵ being associated with a specific gene expression pattern. In addition, valvular n-3 PUFA levels tended to be lower in a group of patients with a history of more rapid progression from moderate to severe AVS, providing a first indication of a role for valvular n-3 PUFA levels in the development of AVD. A link to calcification has previously been suggested on the basis of the inverse association between serum n-3 PUFA levels and coronary artery calcification,²⁶ and the present study extends those observations to valvular heart disease by showing lower n-3 PUFA incorporation in calcified compared with noncalcified human aortic valve tissue.

Using Apoe^{-/-} mice as a model of AVD with the transgenic expression of the *C elegans* Fat-1 gene,¹⁵ which enables the endogenous synthesis of n-3 PUFAs,

we show increased incorporation of n-3 PUFAs and a decreased incorporation of n-6 PUFAs in the aortic valve and in the myocardium. Furthermore, we demonstrate protective effects of n-3 PUFAs in murine AVD. Echocardiographic assessment showed that n-3 PUFAs reduced Vmax and increased cusp separation and that this was associated with changes in valve morphology in terms of a reduction in aortic valve leaflet thickness and area. Moreover, the progressive valvular calcification characteristic of Apoe deficiency^{27,28} was reduced in Fat-1 transgenic Apoe^{-/-} mice. Similar results have been found in *klotho* mutant mice in which EPA significantly reduced arterial calcification, decreased oxidative stress, and downregulated NADPH oxidase-4 expression and activity.²⁹

Under certain conditions, n-3 PUFAs are converted into resolvins, a group of bioactive lipid metabolites with proresolving actions.⁶ The present study is the first to identify resolvins in human aortic valves, of which RvE1 levels significantly decreased in calcified regions. Other lipid mediator pathways with opposed actions such as proinflammatory leukotrienes are increased as aortic valve calcification progresses,^{30,31} which was confirmed for leukotriene B4 in the present study, which also reinforces that calcified valve tissue remains biologically active. As a consequence, the resolvins/leukotriene ratio, a marker of nonresolving inflammation,^{32,33} was lower in calcified regions of human aortic valves, pointing to a local nonresolved inflammation in valve




Figure 7. Fat-1^{tg} reduces leaflet calcification and induces M2 macrophage polarization and targeted deletion of ChemR23 increases leaflet calcification in Apoe^{-/-} and Fat-1^{tg} mice.

A, Quantification of Alizarin Red–stained calcification in 72-week-old Apoe^{-/-}xChemR23^{+/+} (n=12), Apoe^{-/-}xChemR23^{-/-} (n=13), Fat-1^{tg}xApoe^{-/-}xChemR23^{+/+} (n=10), and Fat-1^{tg}xApoe^{-/-}xChemR23^{-/-} (n=13) and representative photomicrographs. **B**, Representative photomicrographs and quantification of leaflets stained with antibodies against the macrophage marker CD68, **(C)** CD206, **(D)** arginase 1 (Arg1), and **(E)** inducible nitric oxide synthase (iNOS) normalized to total aortic valve leaflet area in 72-week-old Apoe^{-/-}xChemR23^{+/+} (n= 11–12), Apoe^{-/-}xChemR23^{-/-} (n=13), Fat-1^{tg}xApoe^{-/-}xChemR23^{+/+} (n= 6–10), and Fat-1^{tg}xApoe^{-/-}xChemR23^{-/-} (n= 10–13). Statistical significance was determined with a 1- or 2-way repeated measures ANOVA followed by Holm-Sidak multiple-comparison test. **P*<0.05; ***P*<0.01; *****P*<0.0001.

calcification. RvE1 signals through ChemR23³⁴ and has been shown, for example, to reduce atherosclerosis⁹ and intimal hyperplasia.^{10,35} RvE1-induced effects on macrophages include decreasing inflammation, inhibiting oxidized low-density lipoprotein uptake, and increasing phagocytosis.⁹ Those proresolving actions are stimulated by a macrophage polarization toward an M2-like or intermediate phenotype.⁷ Consistent with this, ChemR23 in human aortic valves strongly correlated with M2 markers. In addition, we show that Fat-1^{tg} mice exhibited an increased M2 macrophage polarization in murine valves and that those effects were lost in mice lacking ChemR23. In addition to macrophages, RvE1 signaling through ChemR23 on vascular smooth muscle cells diminishes vascular calcification by lowering the expression of bone morphogenetic protein 2 in vascular smooth muscle cells.¹¹ An extrapolation of the latter results to valve calcification can be anticipated on the basis of the dominant valvular ChemR23 expression compared with other SPM receptors, the ChemR23 colocalization with VICs, and the reduced VIC calcification by RvE1 demonstrated in the present study. Taken together, these results suggest that valvular n-3 PUFAs can serve as a substrate for resolvins formation and point to RvE1 signaling through ChemR23-transducing protective effects through both inflammatory and structural valve cells.

In support of therapeutic potential for the latter findings, ChemR23 deletion in Apoe^{-/-} mice accelerated AVD, exhibiting increased Vmax, reduced cusp separation, and increased aortic valve leaflet area and calcification in the present study. We and others have previously established increased RvE1 formation in mice after exogenous n-3 PUFA administration⁹ and Fat-1^{tg} insertion.^{36,37} To determine whether the observed beneficial effects of n-3 PUFAs were mediated by RvE1 signaling through ChemR23, the Fat-1^{tg} was bred into Apoe^{-/-} and ChemR23^{-/-} knockout mice. These experiments confirmed that the observed beneficial effects of n-3 PUFA were completely abolished in mice lacking ChemR23. Moreover, the exacerbated calcification in Apoe^{-/-}xChemR23^{-/-} mice was not reversed by Fat-1^{tg} in the Fat-1^{tg}xApoe^{-/-}xChemR23^{-/-} mouse construct. Taken together, these results demonstrate that the beneficial effects of n-3 PUFA on AVD were driven through ChemR23. However, it cannot be excluded that other n-3 PUFA–derived SPMs also are involved in human AVS. For example, we detect RvD3 formation in human valves, a lipid mediator that has potent anti-inflammatory and proresolving actions that include limiting cytokine production and neutrophil infiltration and enhancing macrophage phagocytosis,³⁸ which may play an important role in the development of AVS.

To validate that the beneficial effects of ChemR23 signaling were independent of hyperlipidemia and

atherosclerosis, we finally used a normolipidemic model by direct aortic valve wire injury in ChemR23^{+/+} and ChemR23^{-/-} mice. Indeed, these experiments demonstrated an increased Vmax and aortic valve leaflet thickness in absence of ChemR23, hence confirming that the beneficial effects on AVD mediated through ChemR23 signaling were reproducible also under normolipidemic condition and in the absence of atherosclerosis.

The strengths of the present study include the exploration of the n-3 PUFA/RvE1/ChemR23 axis in human tissue and cells and in several independent animal models. It should be acknowledged, however, that observational studies in human valves cannot establish causality for the association of valvular n-3 PUFA content with valve calcification and aortic stenosis progression. Likewise, although our murine models present valve thickening, calcification, reduced cusp separation, and hemodynamic signs of accelerated aortic valve flow, it is as yet not known how improvement of those parameters translates into a clinical benefit for patients with AVS. In fact, previous preclinical studies on AVD in animal models have shown other potential treatments for the disease, for example, by lowering plasma cholesterol with the use of statins^{39,40} or by genetic inactivation of the *mtp* gene.⁴¹ However, those results did not translate into reduced aortic stenosis progression in clinical trials.^{42–44} It should also be noted that the models used here did not attain Vmax equivalent to human severe AVS. Technical limitations should also be considered for the use of pulse-wave Doppler with angle correction, which may not optimally capture maximal transvalvular velocities. Although further assessment in more severe AVD models would be of additional value to establish the role of the n-3 PUFA/RvE1/ChemR23 axis over the full disease continuum, the degree of AVD in the models used in the present study may be equal to the mild to moderate AVD that would represent a therapeutic window for a potential medical treatment. Furthermore, the replication of the observations in 2 independent murine AVD models in the present study under different conditions in which wild-type control mice did not exhibit signs of AVD reinforces the reproducibility of the observations.

Conclusions

This study demonstrates for the first time that increased n-3 PUFA content in human aortic valves is associated with less calcification and a specific transcriptomic pattern and that aortic valve n-3 PUFAs decrease AVD in vivo, being consistent for both hemodynamic and morphological criteria and across different murine models. We further decipher the mechanism being mediated through the RvE1 receptor ChemR23. From the translational discoveries presented in this study, the n-3 PUFA-derived RvE1 and its receptor ChemR23 emerge as a key axis in the inhibition of AVD progression. Taken

together with the recent clinical trial demonstrating reduced cardiovascular risk with high-dose EPA,⁵ the results of the present study urge that the n-3 PUFA/RvE1/ChemR23 axis be clinically evaluated as a novel potential therapeutic opportunity to slow AVD progression and to improve the prognosis for these patients.

ARTICLE INFORMATION

Received May 21, 2019; accepted May 13, 2020.

The Data Supplement is available with this article at <https://www.ahajournals.org/doi/suppl/10.1161/circulationaha.119.041868>.

Correspondence

Magnus Bäck, MD, PhD, Department of Cardiology, M85, Karolinska Institutet, Karolinska University Hospital, 141 86 Stockholm, Sweden. Email magnus.back@ki.se

Affiliations

Department of Medicine (G.A., M.C., O.P., S.T., A.L.-F., H.A., M.B.), Division of Physiological Chemistry II, Department of Medical Biochemistry and Biophysics, (C.E.W.), and Department of Molecular Medicine and Surgery (A.F.-C.), Karolinska Institutet, Stockholm, Sweden. Chemistry, Biomaterials and Textiles, RISE Research Institutes of Sweden, Borås, Sweden (P.S.). Theme Heart and Vessels, Division of Valvular and Coronary Disease, Karolinska University Hospital, Stockholm, Sweden. (A.F.-C., M.B.).

Acknowledgments

The authors thank Omegamatrix GmbH (Planegg, Germany) for performing the fatty acid analyses and Carlos Labat and Abdul Rashid Qureshi for the statistical analysis support.

Sources of Funding

This study was supported by the Swedish Research Council (grant 2019-01486), the Swedish Heart and Lung Foundation (grant 20180571), King Gustaf V and Queen Victoria Freemason Foundation, the Stockholm County Council (grant 20170365), and Marianne and Marcus Wallenberg Foundation (grant 2015.0104). G. Artiach was supported by the Swedish Heart and Lung Foundation (grant 20180572). Dr Thul was supported by the Swedish Heart and Lung Foundation (grant 20184251) and through a research fellowship from the Deutsche Forschungsgemeinschaft (grant MU 3857/1–1). Dr Laguna-Fernandez was supported by a fellowship from the Center of Excellence for Research on Inflammation and Cardiovascular Disease (CERIC Linnaeus Program, grant 349-2007-8703) and funds from Nanna Svartz Fond, Fredrik och Ingrid Thuring's Stiftelse, Stiftelsen för Gamla Tjänarinnor, and the Foundation for Geriatric Diseases at Karolinska Institutet. Dr Arnardottir was supported by the Swedish Heart and Lung Foundation (grant 20170311), the Foundation for Geriatric Diseases at Karolinska Institutet, and a European Union Horizon 2020 Marie Skłodowska-Curie fellowship (under grant agreement 656817).

Disclosures

None.

Supplemental Materials

Expanded Methods
Data Supplement Figures I–II
Data Supplement Tables I–IX
References 45–53

REFERENCES

1. Turina J, Hess O, Sepulcri F, Krayenbuehl HP. Spontaneous course of aortic valve disease. *Eur Heart J*. 1987;8:471–483. doi: 10.1093/oxfordjournals.eurheartj.a062307

2. Bäck M, Gasser TC, Michel JB, Caligiuri G. Biomechanical factors in the biology of aortic wall and aortic valve diseases. *Cardiovasc Res*. 2013;99:232–241. doi: 10.1093/cvr/cvt040
3. Kleinauskienė R, Jonkaitienė R. Degenerative aortic stenosis, dyslipidemia and possibilities of medical treatment. *Medicina (Kaunas)*. 2018;54:24. doi: 10.3390/medicina5402024
4. Al-Azizi K, Hamandi M, Mack M. Clinical trials of transcatheter aortic valve replacement. *Heart*. 2019;105(suppl 2):s6–s9. doi: 10.1136/heartjnl-2018-313511
5. Bhatt DL, Steg PG, Miller M, Brinton EA, Jacobson TA, Ketchum SB, Doyle RT Jr, Juliano RA, Jiao L, Granowitz C, et al; REDUCE-IT Investigators. Cardiovascular risk reduction with icosapent ethyl for hypertriglyceridemia. *N Engl J Med*. 2019;380:11–22. doi: 10.1056/NEJMoa1812792
6. Serhan CN, Chiang N, Dalli J, Levy BD. Lipid mediators in the resolution of inflammation. *Cold Spring Harb Perspect Biol*. 2014;7:a016311. doi: 10.1101/cshperspect.a016311
7. Bäck M, Yurdagül A Jr, Tabas I, Öörni K, Kovanen PT. Inflammation and its resolution in atherosclerosis: mediators and therapeutic opportunities. *Nat Rev Cardiol*. 2019;16:389–406. doi: 10.1038/s41569-019-0169-2
8. Pirault J, Bäck M. Lipoxin and resolvin receptors transducing the resolution of inflammation in cardiovascular disease. *Front Pharmacol*. 2018;9:1273. doi: 10.3389/fphar.2018.01273
9. Laguna-Fernandez A, Checa A, Carracedo M, Artiach G, Petri MH, Baumgartner R, Forsteza MJ, Jiang X, Andonova T, Walker ME, et al. ERV1/ChemR23 signaling protects against atherosclerosis by modifying oxidized low-density lipoprotein uptake and phagocytosis in macrophages. *Circulation*. 2018;138:1693–1705. doi: 10.1161/CIRCULATIONAHA.117.032801
10. Liu G, Gong Y, Zhang R, Piao L, Li X, Liu Q, Yan S, Shen Y, Guo S, Zhu M, et al. Resolvin E1 attenuates injury-induced vascular neointimal formation by inhibition of inflammatory responses and vascular smooth muscle cell migration. *FASEB J*. 2018;32:5413–5425. doi: 10.1096/fj.201800173R
11. Carracedo M, Artiach G, Witasz A, Clària J, Carlström M, Laguna-Fernandez A, Stenvinkel P, Bäck M. The G-protein coupled receptor ChemR23 determines smooth muscle cell phenotypic switching to enhance high phosphate-induced vascular calcification. *Cardiovasc Res*. 2019;115:1557–1566. doi: 10.1093/cvr/cvy316
12. English JT, Norris PC, Hodges RR, Dartt DA, Serhan CN. Identification and profiling of specialized pro-resolving mediators in human tears by lipid mediator metabolomics. *Prostaglandins Leukot Essent Fatty Acids*. 2017;117:17–27. doi: 10.1016/j.plefa.2017.01.004
13. Petri MH, Laguna-Fernandez A, Arnardottir H, Wheelock CE, Perretti M, Hansson GK, Bäck M. Aspirin-triggered lipoxin A4 inhibits atherosclerosis progression in apolipoprotein E-/- mice. *Br J Pharmacol*. 2017;174:4043–4054. doi: 10.1111/bph.13707
14. Colas RA, Shinohara M, Dalli J, Chiang N, Serhan CN. Identification and signature profiles for pro-resolving and inflammatory lipid mediators in human tissue. *Am J Physiol Cell Physiol*. 2014;307:C39–C54. doi: 10.1152/ajpcell.00024.2014
15. Kang JX, Wang J, Wu L, Kang ZB. Transgenic mice: fat-1 mice convert n-6 to n-3 fatty acids. *Nature*. 2004;427:504. doi: 10.1038/427504a
16. Kutner MH, Nachtsheim CJ, Neter J, Li W. *Applied Linear Statistical Models*. 5th ed. London, UK: McGraw-Hill/Irwin; 2005.
17. Serhan CN, Hong S, Gronert K, Colgan SP, Devchand PR, Mirick G, Moussignac RL. Resolvins: a family of bioactive products of omega-3 fatty acid transformation circuits initiated by aspirin treatment that counter proinflammation signals. *J Exp Med*. 2002;196:1025–1037. doi: 10.1084/jem.20020760
18. Serhan CN, Clish CB, Brannon J, Colgan SP, Chiang N, Gronert K. Novel functional sets of lipid-derived mediators with antiinflammatory actions generated from omega-3 fatty acids via cyclooxygenase 2-nonsteroidal antiinflammatory drugs and transcellular processing. *J Exp Med*. 2000;192:1197–1204. doi: 10.1084/jem.192.8.1197
19. Casaciang-Verzosa G, Enriquez-Sarano M, Villaraga HR, Miller JD. Echocardiographic approaches and protocols for comprehensive phenotypic characterization of valvular heart disease in mice. *J Vis Exp*. 2017;e54110. doi: 10.3791/54110
20. Huang Y, Powers C, Moore V, Schafer C, Ren M, Phoon CK, James JF, Glukhov AV, Javadov S, Vaz FM, et al. The PPAR pan-agonist bezafibrate ameliorates cardiomyopathy in a mouse model of Barth syndrome. *Orphanet J Rare Dis*. 2017;12:49. doi: 10.1186/s13023-017-0605-5
21. Honda S, Miyamoto T, Watanabe T, Narumi T, Kadowaki S, Honda Y, Otaki Y, Hasegawa H, Netsu S, Funayama A, et al. A novel mouse model of aortic valve stenosis induced by direct wire injury. *Arterioscler Thromb Vasc Biol*. 2014;34:270–278. doi: 10.1161/ATVBAHA.113.302610
22. Niepmann ST, Steffen E, Zietzer A, Adam M, Nordsiek J, Gyamfi-Poku I, Playda K, Sinning JM, Baldus S, Kelm M, et al. Graded murine wire-induced aortic valve stenosis model mimics human functional and morphological disease phenotype. *Clin Res Cardiol*. 2019;108:847–856. doi: 10.1007/s00392-019-01413-1
23. Bhatt DL, Steg PG, Miller M, Brinton EA, Jacobson TA, Ketchum SB, Doyle RT Jr, Juliano RA, Jiao L, Granowitz C, et al; REDUCE-IT Investigators. Effects of icosapent ethyl on total ischemic events: from REDUCE-IT. *J Am Coll Cardiol*. 2019;73:2791–2802. doi: 10.1016/j.jacc.2019.02.032
24. Block RC, Harris WS, Pottala JV. Determinants of blood cell omega-3 fatty acid content. *Open Biomark J*. 2008;1:1–6. doi: 10.2174/1875318300801010001
25. Harris WS, Sands SA, Windsor SL, Ali HA, Stevens TL, Magalski A, Porter CB, Borkon AM. Omega-3 fatty acids in cardiac biopsies from heart transplantation patients: correlation with erythrocytes and response to supplementation. *Circulation*. 2004;110:1645–1649. doi: 10.1161/01.CIR.0000142292.10048.B2
26. Sekikawa A, Miura K, Lee S, Fujiyoshi A, Edmundowicz D, Kadowaki T, Evans RW, Kadowaki S, Sutton-Tyrrell K, Okamura T, et al; ERA JUMP Study Group. Long chain n-3 polyunsaturated fatty acids and incidence rate of coronary artery calcification in Japanese men in Japan and white men in the USA: population based prospective cohort study. *Heart*. 2014;100:569–573. doi: 10.1136/heartjnl-2013-304421
27. Tanaka K, Sata M, Fukuda D, Suematsu Y, Motomura N, Takamoto S, Hirata Y, Nagai R. Age-associated aortic stenosis in apolipoprotein E-deficient mice. *J Am Coll Cardiol*. 2005;46:134–141. doi: 10.1016/j.jacc.2005.03.058
28. Aikawa E, Nahrendorf M, Sosnovik D, Lok VM, Jaffer FA, Aikawa M, Weissleder R. Multimodality molecular imaging identifies proteolytic and osteogenic activities in early aortic valve disease. *Circulation*. 2007;115:377–386. doi: 10.1161/CIRCULATIONAHA.106.654913
29. Nakamura K, Miura D, Saito Y, Yunoki K, Koyama Y, Satoh M, Kondo M, Osawa K, Hatipoglu OF, Miyoshi T, et al. Eicosapentaenoic acid prevents arterial calcification in klotho mutant mice. *PLoS One*. 2017;12:e0181009. doi: 10.1371/journal.pone.0181009
30. Nagy E, Andersson DC, Caidahl K, Eriksson MJ, Eriksson P, Franco-Cereceda A, Hansson GK, Bäck M. Upregulation of the 5-lipoxygenase pathway in human aortic valves correlates with severity of stenosis and leads to leukotriene-induced effects on valvular myofibroblasts. *Circulation*. 2011;123:1316–1325. doi: 10.1161/CIRCULATIONAHA.110.966846
31. Kochtebane N, Passetfort S, Choqueux C, Ainoun F, Achour L, Michel JB, Bäck M, Jacob MP. Release of leukotriene B4, transforming growth factor-beta1 and microparticles in relation to aortic valve calcification. *J Heart Valve Dis*. 2013;22:782–788.
32. Fredman G, Hellmann J, Proto JD, Kuriakose G, Colas RA, Dorweiler B, Connolly ES, Solomon R, Jones DM, Heyer EJ, et al. An imbalance between specialized pro-resolving lipid mediators and pro-inflammatory leukotrienes promotes instability of atherosclerotic plaques. *Nat Commun*. 2016;7:12859. doi: 10.1038/ncomms12859
33. Thul S, Labat C, Temmar M, Benetos A, Bäck M. Low salivary resolvin D1 to leukotriene B4 ratio predicts carotid intima media thickness: a novel biomarker of non-resolving vascular inflammation. *Eur J Prev Cardiol*. 2017;24:903–906. doi: 10.1177/2047487317694464
34. Arita M, Bianchini F, Aliberti J, Sher A, Chiang N, Hong S, Yang R, Petasis NA, Serhan CN. Stereochemical assignment, antiinflammatory properties, and receptor for the omega-3 lipid mediator resolvin E1. *J Exp Med*. 2005;201:713–722. doi: 10.1084/jem.20042031
35. Artiach G, Carracedo M, Clària J, Laguna-Fernandez A, Bäck M. Opposing effects on vascular smooth muscle cell proliferation and macrophage-induced inflammation reveal a protective role for the proresolving lipid mediator receptor ChemR23 in intimal hyperplasia. *Front Pharmacol*. 2018;9:1327. doi: 10.3389/fphar.2018.01327
36. Bilal S, Haworth O, Wu L, Weylandt KH, Levy BD, Kang JX. Fat-1 transgenic mice with elevated omega-3 fatty acids are protected from allergic airway responses. *Biochim Biophys Acta*. 2011;1812:1164–1169. doi: 10.1016/j.bbdis.2011.05.002
37. Hudert CA, Weylandt KH, Lu Y, Wang J, Hong S, Dignass A, Serhan CN, Kang JX. Transgenic mice rich in endogenous omega-3 fatty acids are protected from colitis. *Proc Natl Acad Sci USA*. 2006;103:11276–11281. doi: 10.1073/pnas.0601280103
38. Dalli J, Winkler JW, Colas RA, Arnardottir H, Cheng CY, Chiang N, Petasis NA, Serhan CN. Resolvin D3 and aspirin-triggered resolvin D3 are potent immunoresolvents. *Chem Biol*. 2013;20:188–201. doi: 10.1016/j.chembiol.2012.11.010

39. Rajamannan NM, Subramaniam M, Stock SR, Stone NJ, Springett M, Ignatiev KI, McConnell JP, Singh RJ, Bonow RO, Spelsberg TC. Atorvastatin inhibits calcification and enhances nitric oxide synthase production in the hypercholesterolaemic aortic valve. *Heart*. 2005;91:806–810. doi: 10.1136/hrt.2003.029785
40. Rajamannan NM, Subramaniam M, Springett M, Sebo TC, Niekrasz M, McConnell JP, Singh RJ, Stone NJ, Bonow RO, Spelsberg TC. Atorvastatin inhibits hypercholesterolemia-induced cellular proliferation and bone matrix production in the rabbit aortic valve. *Circulation*. 2002;105:2660–2665. doi: 10.1161/01.cir.0000017435.87463.72
41. Miller JD, Weiss RM, Serrano KM, Brooks RM 2nd, Berry CJ, Zimmerman K, Young SG, Heistad DD. Lowering plasma cholesterol levels halts progression of aortic valve disease in mice. *Circulation*. 2009;119:2693–2701. doi: 10.1161/CIRCULATIONAHA.108.834614
42. Cowell SJ, Newby DE, Prescott RJ, Bloomfield P, Reid J, Northridge DB, Boon NA; Scottish Aortic Stenosis and Lipid Lowering Trial, Impact on Regression (SALTIRE) Investigators. A randomized trial of intensive lipid-lowering therapy in calcific aortic stenosis. *N Engl J Med*. 2005;352:2389–2397. doi: 10.1056/NEJMoa043876
43. Rossebø AB, Pedersen TR, Boman K, Brudi P, Chambers JB, Egstrup K, Gerds E, Gohlke-Bärwolf C, Holme I, Kesäniemi YA, et al; SEAS Investigators. Intensive lipid lowering with simvastatin and ezetimibe in aortic stenosis. *N Engl J Med*. 2008;359:1343–1356. doi: 10.1056/NEJMoa0804602
44. Chan KL, Teo K, Dumesnil JG, Ni A, Tam J; ASTRONOMER Investigators. Effect of lipid lowering with rosuvastatin on progression of aortic stenosis: results of the Aortic Stenosis Progression Observation: Measuring Effects of Rosuvastatin (ASTRONOMER) trial. *Circulation*. 2010;121:306–314. doi: 10.1161/CIRCULATIONAHA.109.900027
45. Arnold C, Markovic M, Blossey K, Wallukat G, Fischer R, Dechend R, Konkel A, von Schacky C, Luft FC, Muller DN, et al. Arachidonic acid-metabolizing cytochrome P450 enzymes are targets of {omega}-3 fatty acids. *J Biol Chem*. 2010;285:32720–32733. doi: 10.1074/jbc.M110.118406
46. von Schacky C, Harris WS. Cardiovascular risk and the omega-3 index. *J Cardiovasc Med (Hagerstown)*. 2007;8(suppl 1):S46–S49. doi: 10.2459/01.JCM.0000289273.87803.87
47. Baumgartner H, Falk V, Bax JJ, De Bonis M, Hamm C, Holm PJ, Jung B, Lancellotti P, Lansac E, Rodriguez Muñoz D, et al; ESC Scientific Document Group. 2017 ESC/EACTS guidelines for the management of valvular heart disease. *Eur Heart J*. 2017;38:2739–2791. doi: 10.1093/eurheartj/ehx391
48. Mercier N, Pawelzik SC, Pirault J, Carracedo M, Persson O, Wollensack B, Franco-Cereceda A, Bäck M. Semicarbazide-sensitive amine oxidase increases in calcific aortic valve stenosis and contributes to valvular interstitial cell calcification. *Oxid Med Cell Longev*. 2020;2020:5197376. doi: 10.1155/2020/5197376
49. Touboul D, Laprévotte O, Brunelle A. Micrometric molecular histology of lipids by mass spectrometry imaging. *Curr Opin Chem Biol*. 2011;15:725–732. doi: 10.1016/j.cbpa.2011.04.017
50. Lindgren J, Kuriyama T, Madsen H, Sjövall P, Zheng W, Uvdal P, Engdahl A, Moyer AE, Gren JA, Kamezaki N, et al. Biochemistry and adaptive colouration of an exceptionally preserved juvenile fossil sea turtle. *Sci Rep*. 2017;7:13324. doi: 10.1038/s41598-017-13187-5
51. Li L, Guo X, Chen Y, Yin H, Li J, Doan J, Liu Q. Assessment of cardiac morphological and functional changes in mouse model of transverse aortic constriction by echocardiographic imaging. *J Vis Exp*. 2016:e54101. doi: 10.3791/54101
52. Simolin MA, Pedersen TX, Bro S, Mäyränpää MI, Helske S, Nielsen LB, Kovanen PT. ACE inhibition attenuates uremia-induced aortic valve thickening in a novel mouse model. *BMC Cardiovasc Disord*. 2009;9:10. doi: 10.1186/1471-2261-9-10
53. Mjaatvedt CH, Kern CB, Norris RA, Fairey S, Cave CL. Normal distribution of melanocytes in the mouse heart. *Anat Rec A Discov Mol Cell Evol Biol*. 2005;285:748–757. doi: 10.1002/ar.a.20210